Dissociated Response and Clinical Impact in Patients Treated With Nivolumab Monotherapy

Yuki Sato (yuki1130sato@gmail.com)  
Department of Respiratory Medicine, Kobe City Medical Center General Hospital 2-1-1 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan  
https://orcid.org/0000-0002-7829-7524

Takeshi Morimoto  
Hyogo Ika Daigaku

Shigeo Hara  
Kobe City Medical Center General Hospital: Kobe Shiritsu Iryo Center Chuo Shimin Byoin

Kazuma Nagata  
Kobe City Medical Center General Hospital: Kobe Shiritsu Iryo Center Chuo Shimin Byoin

Kazutaka Hosoya  
Kobe City Medical Center General Hospital: Kobe Shiritsu Iryo Center Chuo Shimin Byoin

Atsushi Nakagawa  
Kobe City Medical Center General Hospital: Kobe Shiritsu Iryo Center Chuo Shimin Byoin

Ryo Tachikawa  
Kobe City Medical Center General Hospital: Kobe Shiritsu Iryo Center Chuo Shimin Byoin

Keisuke Tomii  
Kobe City Medical Center General Hospital: Kobe Shiritsu Iryo Center Chuo Shimin Byoin

Research article

Keywords: dissociated response, mixed response, nivolumab, immunotherapy, immune checkpoint inhibitor, non-small cell lung cancer

DOI: https://doi.org/10.21203/rs.3.rs-77417/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. 
Read Full License
Abstract

Background: Immune checkpoint inhibitors (ICIs) are effective for previously treated patients with advanced non-small cell lung cancer (NSCLC). However, an unconventional response pattern is sometimes encountered. A dissociated response (DR), characterized by some lesions shrinking and others growing, has been recognized with ICI treatment. In this study, we examined the characteristics and treatment outcomes of DR in previously treated NSCLC patients, receiving nivolumab monotherapy, and aimed to provide insight on how to potentially improve the management of this group of patients.

Methods: We conducted a retrospective cohort study of previously treated patients with advanced NSCLC who received nivolumab. We assessed the tumor response of each organ using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria at the first radiologic evaluation. We investigated treatment outcome and compared overall survival using the Kaplan-Meier Method and log-rank tests. Further, we conducted the same analysis in patients who had previously received chemotherapy or tyrosine kinase inhibitor therapy in our hospital.

Results: Between April 2016 and September 2018, 107 patients who received nivolumab fulfilled the inclusion criteria. Of them, 5 (5%) patients showed a DR. There were no specific differences in characteristics between DR and non-DR cases. Patients showing DR had significantly longer overall survival than those showing concordant progressive disease (not reached vs. 8.0 months, p = 0.039). The frequencies of DR in the ICI, chemotherapy, and tyrosine kinase inhibitor-treated cohorts were 5%, 1%, and 4%, respectively.

Conclusion: DR was uncommon, but this presented a distinctive pattern of nivolumab response. Some patients might benefit from continuing nivolumab therapy and may achieve a longer overall survival. Further research is required to elucidate the characteristics, treatment strategies, and underlying mechanisms of DR in NSCLC patients.

Background

Lung cancer is the leading cause of cancer-related deaths worldwide [1]. Non-small cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancers, and in most cases is unresectable and metastatic at the time of initial diagnosis [2]. Recently, immune checkpoint inhibitors (ICIs), which inhibit the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) axis, have demonstrated impressive efficacy in patients with advanced NSCLC. Nivolumab (Bristol-Myers Squibb, Lawrenceville, NJ, USA) has been approved as a standard treatment option for previously treated NSCLC after accumulation of data from the CheckMate-017 and CheckMate-057 clinical studies [3, 4].

The response patterns of tumors treated with ICIs may differ from those of tumors treated with conventional chemotherapeutic agents or targeted therapies, owing to their unique mechanism of action [5]. First, an initial flare-up followed by tumor shrinkage, defined as pseudoprogression, has been reported [6, 7]. Second, rapid tumor progression following ICI administration, defined as hyperprogression, has also
been described [8, 9]. Finally, previous reports have recognized the occurrence of a ‘mixed tumor response’ phenomenon in some patients, whereby some lesions decrease in size and others grow [10, 11]. These heterogeneous response patterns of individual lesions in the same patient have been defined a “dissociated response (DR)” [12]. This atypical response raises the confusion of stopping or continuing ICI treatment. To date, there are limited data available on the incidence of DR, and its clinical significance has not been fully understood or investigated [13].

Thus, in this study, we aimed to demonstrate the prevalence and clinical course of patients exhibiting a DR following treatment with nivolumab and to provide insight on how to potentially improve the management of this group of patients.

Methods

Patient inclusion criteria

We retrospectively analyzed patients with previously treated advanced NSCLC, who received nivolumab monotherapy in the Kobe City Medical Center General Hospital between April 2016 and September 2018 (Figure 1). Patients without any measurable lesions or those whose response to treatment was not evaluated were excluded. Patients who reported never having smoked were defined as non-smokers, those who had smoked within 1 year of diagnosis were categorized as current smokers, and the remaining patients were considered former smokers. All patients were classified on the basis of their clinical stage according to the 8th edition TNM classification criteria [14]. Overall survival (OS) was defined as the period from the day of commencement of nivolumab treatment until death from any cause or the end of the follow-up period. The cutoff date for data collection was May 31, 2019. We isolated tumor DNA from various specimens and analyzed the mutational status of the epidermal growth factor receptor (EGFR) gene at exons 18–21 using the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp method, as described previously [15]. Anaplastic lymphoma kinase (ALK) translocation was assessed by immunohistochemistry or fluorescence in situ hybridization break-apart probes, as described previously [16]. PD-L1 tumor proportion score (TPS) was evaluated by the 22C3 assay [17]. This study was approved by the Ethics Review Board or Institutional Review Board of each participating institute (zn190108). Informed consent was not required owing to the retrospective nature of the study. Tumors were assessed according to two categories: RECIST version 1.1 and iRECIST criteria, which were used in trials to evaluate the efficacy of immunotherapeutics [18, 19]. A durable clinical benefit was defined as the duration of complete response (CR)/partial response (PR) (the sum of the longest diameter [SLD] of the target lesions was decreased by at least 30% from the baseline)/stable disease (SD) over 6 months [20].

Definition of DR

The DR was previously described as a concomitant decrease in tumoral elements and an increase in other elements [12, 13, 21]. Importantly, no standardized definition of DR exists in the currently available literature. To extract patients with an apparent DR, we defined the specific criteria described below. We
reviewed baseline radiographic data and the first computed tomography/magnetic resonance imaging (CT/MRI) results (performed between 6 to 12 weeks after commencement of nivolumab monotherapy), and evaluated measurable lesions per organ and decided its response. Measurable lesions were defined as lesions measuring over 10 mm in longest diameter or over 15 mm in short axis diameter for lymph nodes. We examined the tumor response by organs by selecting up to two measurable lesions in one organ. We defined the DR according to the following criteria: 1) patients who have both CR/PR organs and progressive disease (PD, at least a 20% increase and at least 5 mm from the nadir in the SLD of the target lesions) simultaneously; and 2) patients who had all CR/PR organs but with the appearance of new lesions or apparent deterioration of unmeasurable lesions. All patients received CT scans within 30 days before commencing nivolumab treatment. Lesions treated with concomitant radiation therapy were excluded from this analysis. All radiological images were evaluated by three independent specialists (pulmonologist and radiologist). In cases of disagreement, the radiographic data were re-examined until a consensus was reached through central review.

**Pathological analysis of the DR site**

We collected pathological specimens of progressive lesions in patients with DR and compared these with the primary lesions. Hematoxylin and eosin-stained sections were evaluated by two experienced pathologists.

**Comparison analysis of cytotoxic chemotherapy and tyrosine kinase inhibitor therapy**

To clarify the pattern of DR incidence across treatments, we retrospectively analyzed patients who were treated with a first-line cytotoxic chemotherapy agent or first-line EGFR tyrosine kinase inhibitor (TKI) in the Kobe City Medical Center General Hospital between April 2016 and September 2018. We reviewed patients with a DR using the definition described above.

**Statistical analysis**

Continuous variables were analyzed using the Student’s *t*-test. Dichotomous variables were analyzed using Pearson’s $\chi^2$ or Fisher’s exact test, as appropriate. Kaplan-Meier’s method was used to estimate survival outcomes, which were compared using the log-rank test between the groups. A $P$-value of <0.05 indicated statistical significance. We conducted the statistical analyses using JMP 11 software (SAS Institute, Cary, NC, USA).

**Results**

**Patient characteristics and treatment outcome**

Of the 114 patients who were previously treated for advanced NSCLC and who received nivolumab therapy, 7 patients were excluded from the study because they did not have RECIST-defined measurable lesions or they were not adequately evaluated for tumor response (Figure 1). Finally, 107 patients were
included in the study; the patients’ characteristics are summarized in Table 1. The mean age of included patients was 68.2 years, and most patients were men (72%), had a history of smoking (75%), Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 (93%), and adenocarcinoma histology (74%). The total objective response by RECIST criteria was 22%; 19% of the patients had SD, and 59% had PD. At the time of analysis, 47 OS events (44%) had occurred. The median OS and estimated 1-year OS rate were 16.3 months and 42%, respectively.

Characteristics and treatment course of cases with DR

DR was observed in 5 patients (5%). The comparison between DR and non-DR patients revealed no significant differences in the patients’ characteristics (Table 1). Treatment course and a representative CT scan of patients with DR are shown in Figure 2.

Patient No. 6 was a 68-year-old man with advanced lung adenocarcinoma (Figure 2A). He started nivolumab as a second-line therapy. After the four cycles of nivolumab treatment, his primary lesion reduced in size (33 mm to 22 mm), although a new metastatic lesion (10 mm) in his brain was detected on the MRI scan; therefore, DR was diagnosed. His RECIST-defined tumor assessment was PD due to the new lesion and unconfirmed progressive disease (iUPD) by the iRECIST criteria. Nivolumab treatment was continued; thereafter, his tumor remained stable (iUPD by the iRECIST criteria). After 21 cycles of nivolumab, he developed immune-related diarrhea, and nivolumab was permanently interrupted. His tumors remained stable. After 729 days of nivolumab treatment, he experienced iPD by the iRECIST criteria (PD in primary lesion and brain metastasis).

Patient No. 28 was a 53-year-old woman with advanced lung adenocarcinoma. She began nivolumab as a third-line therapy (Figure 2B). After 5 cycles of nivolumab, her primary lesion reduced in size; however, her axial lymph node was enlarged (minimal diameter was 15 mm), and DR was diagnosed. Her RECIST-defined tumor response was PD, and her iRECIST-defined tumor assessment was iUPD. Nivolumab treatment was continued for another 6 cycles, until treatment was discontinued because of the onset of immune-related diarrhea. Her tumor remained stable (iUPD by iRECIST criteria). After 234 days of nivolumab treatment, the tumors were radiologically stable, but her serum levels of carcinoembryonic antigen (CEA) and cytokeratin-19-fragment (CYFRA) were elevated. Her attending physician diagnosed the condition as clinical PD, and she started fourth-line chemotherapy.

Patient No. 40 was an 80-year-old man with advanced lung adenocarcinoma (Figure 2C), and he was given nivolumab as a third-line therapy. After 3 cycles of nivolumab, his primary lesion was enlarged and pleural effusion was increased, although his pleural dissemination was reduced; thus, DR was diagnosed. His overall tumor assessment by RECIST was SD and that by iRECIST was iSD, and nivolumab treatment was continued. After 3 additional cycles of nivolumab, his primary lesion enlarged and was diagnosed as RECIST-defined PD.

A summary of the patients’ clinical courses is shown in Figure 3 and Supplementary Table 1. At DR diagnosis, 2 patients showed RECIST-defined PD and 3 patients showed RECIST-defined SD. The PD-L1
TPSs for these patients were 10% (No. 6), 30% (No. 28), 0% (No. 40), unknown because of low amount of specimen (No. 62), and 1% (No. 65). The times to treatment failure from commencement of nivolumab were 729, 234, 100, 174, and 151 days, respectively. Of the 5 patients, 2 achieved a durable clinical benefit. In this cohort, all patients continued nivolumab after DR, and local therapy was not conducted for the progressive lesion.

**Pathological analysis of the DR site**

Of the 5 patients with DR, 2 consented to tumor biopsies of the growing lesion (No. 40 and No. 65). In Patient No. 40, adenocarcinoma was diagnosed in the cell block analysis of the pleural effusion (Supplementary Figure 1A), which showed the same histology as the primary lesion (Supplementary Figure 1B). There was no evidence of other etiologies of pleural effusion, such as infection. Patient No. 65 underwent kidney biopsy, which revealed adenocarcinoma (Supplementary Figure 1C). Interestingly, this patient had an adenosquamous histology in the primary lesion (Supplementary Figure 1D); thus, a histological temporal heterogeneity was found between the primary and metastatic lesion.

**Response patterns and OS**

Patients showing DR had significantly longer OS than those showing concordant PD (PD without DR) (not reached vs. 8.0 months, respectively; \( p = 0.039 \)). In addition, there was no significant difference in the OS between patients who showed concordant PR (PR without DR) and those who showed concordant SD (SD without DR) (not reached and not reached, respectively; \( p = 0.19 \) and \( p = 0.79 \), respectively). The data and Kaplan-Meier curves for OS are shown in Figure 4 and Supplementary table 2.

**Comparison between ICI, chemotherapy, and TKI treatment**

There were 150 patients in the chemotherapy group and 92 patients in the TKI group, and the frequencies of DR were 1% (2/150) and 4% (4/92), respectively (Figure 5). Increased frequencies of DR were observed in the ICI and TKI groups compared with that in the chemotherapy group; however, the differences were not statistically significant. None of the patients in the chemotherapy and TKI cohorts achieved durable clinical benefit.

**Discussion**

Our study evaluated the occurrence of DR after commencing nivolumab treatment in patients with previously treated NSCLC. We evaluated the patient characteristics, treatment course after DR, and histological findings and compared the prevalence of DR in the nivolumab treatment cohort with those in the chemotherapy and TKI cohorts. To the best of our knowledge, this is the first comprehensive report of DR of ICI monotherapy describing the prognostic impact of DR.

In our study, 5% of patients with NSCLC exhibited DR after starting nivolumab treatment, and this response was observed across all organs. The DR was first described as a “mixed response” in melanoma patients in a prospective clinical trial of immunotherapy [22]. Moreover, DR was also observed...
in a retrospective study of NSCLC cases with a frequency of 7.5% [12]. Importantly, DR is a different phenomenon than pseudoprogression. Pseudoprogression is typically defined as the initial increase of tumor size or the presence of new lesions prior to a decrease in size [6]. In our cohorts, none of our DR cases showed a decrease in size, and all remained SD. Taken together, we speculate that DR is a distinctive response pattern of ICI monotherapy, irrespective of the cancer type or organ involved.

Such response patterns present a particular challenge for patient management, in terms of whether the patient should switch to next-line treatment, continue the original regimen, be followed-up frequently, or commence local therapy. In our cohort, all patients who exhibited DR continued nivolumab treatment, and 40% of patients (Patients No. 6 and No. 28) achieved a durable clinical benefit [20]. Moreover, better survival was observed in patients with DR than in patients with concordant PD. In previous studies, ICI benefits were observed in 20–50% of patients who exhibited DR [11, 12]. We should be aware that DR does not always represent ICI resistance, and switching ICI treatment to another systemic chemotherapy defined according to RECIST ver1.1 may be an early decision. However, continuing ICI in carefully selected patients whose clinical conditions are stable and who have not experienced severe toxicities is a possible treatment option. Taken together, using the iRECIST guideline, developed to avoid the underestimations of RECIST ver1.1, may be a better strategy. There is need for further investigation into the potential benefits and risks of DR in patients who continue immunotherapy.

The underlying mechanisms for a DR have not been understood. A possible explanation is that DR results from immune reactions, such as massive immune cell infiltrations or the sarcoid reaction, which have been reported in previous studies [23, 24]. A second possible explanation is that the temporal heterogeneity of the tumor, such as the PD-L1 TPS and immune status, may account for the DR [25]. In our cohort, no specific immune reactions were observed, and one patient exhibited tumor histology heterogeneity between primary and metastatic lesions.

The DR was previously reported as a relatively common phenomenon in acquired resistance following EGFR TKI monotherapy for EGFR mutation positive NSCLC (identified in 20% of patients), and the mechanism was speculated to be the genetic or tumoral heterogeneity [26-29]. The previously reported prevalence is higher than that in our findings, as the radiologic definition is not same. Importantly, DR was considered an independent worse predictive factor in the TKI cohort, and we did not observe any clinical benefit in patients who received chemotherapy or TKI treatment in this study. We should recognize that the clinical significance of DR occurring during chemotherapy or TKI therapy is different from that occurring during ICI therapy.

Our study may contribute in establishing appropriate management plans for patients who exhibit DR during ICI treatment; however, it has several limitations. First, it was a retrospective study that included a small number of subjects from a single institution, owing to the rarity of DR. Second, all patients received nivolumab after DR, and we have no data on patients who stopped ICIs or commenced local ablative therapy.
Conclusion

DR was an uncommon but distinctive response pattern in nivolumab monotherapy, and a durable benefit was observed in patients exhibiting a DR. The survival benefit in DR cases was better than in concordant PD cases. These data provide scope for improving ICI therapy for NSCLC patients. Thus, in patients presenting DR, continuing nivolumab therapy may be beneficial and may allow patients to achieve a longer OS. Further research is required to elucidate the characteristics, treatment strategies, and underlying mechanisms of DR.

List Of Abbreviations

CR=complete response; DR=dissociated response; ECOG-PS=Eastern Cooperative Oncology Group performance status; EGFR=epidermal growth factor receptor; ICI=immune checkpoint inhibitor; NSCLC=non-small cell lung cancer; OS=overall survival; PD=progressive disease; PD-1=programmed death protein 1; PD-L1=programmed death ligand 1; PR=partial response; RECIST=Response Evaluation Criteria in Solid Tumors; SD=stable disease; SLD=sum of the longest diameter; TPS=tumor proportion score; TKI=tyrosine kinase inhibitor; iUPD=unconfirmed progressive disease

Declarations

Ethics approval and consent to participate

This study was conducted with the approval of the Kobe City Medical Center General Hospital Ethics Committee (No. zn190108).

Consent for publication

Informed consent was not required owing to the retrospective nature of the study.

Availability of data and materials

All datasets on which the conclusions of this paper rely are available on request.

Competing interests

Dr. Sato has received lecture fees from Ono Pharmaceutical Co., Ltd. (Osaka, Japan). Dr. Morimoto has received manuscript preparation fees and was on an advisory board of Bristol-Myers Squibb K.K. (Tokyo, Japan). Dr Hosoya has received lecture fees from Ono Pharmaceutical Co., Ltd. (Osaka, Japan). All remaining authors have no conflicts of interest to declare. We wish to confirm that there are no other known conflicts of interest associated with this publication. Further, there was no significant financial support for this work that could have influenced its outcome.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Authors' contributions

Yuki Sato: guarantor of the paper and responsible for the integrity of the work as a whole, from inception to the published article. Takeshi Morimoto: data analysis, interpretation, and revision of manuscript. Shigeo Hara: conducted pathological analysis. Kazuma Nagata: study conception and design. Kazutaka Hosoya, Atsushi Nakagawa, Ryo Tachikawa, and Keisuke Tomii: data acquisition and radiological assessment. All authors have read and approved the manuscript as submitted.

Acknowledgements

The authors would like to thank Keiko Sakuragawa and Kanako Masuta for her administrative assistance, and Yukihiro Imai for conducting the pathological analyses. We would like to thank Editage (www.editage.com) for English language editing.

Authors' information

Yuki Sato: yuki1130sato@gmail.com; Takeshi Morimoto: morimoto@kuhp.kyoto-u.ac.jp; Shigeo Hara: shigeo_hara@kcho.jp; Kazuma Nagata: knagata@kcho.jp; Kazutaka Hosoya: hsyn0917@gmail.com; Atsushi Nakagawa: a.nakagawa@kcho.jp; Ryo Tachikawa: ryotkw@gmail.com; Keisuke Tomii: ktomii@kcho.jp

References

1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2019. CA Cancer J Clin 2019, 69(1):7-34.
2. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008, 83(5):584-594.
3. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E et al: Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015, 373(2):123-135.
4. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E et al: Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015, 373(17):1627-1639.
5. Borcoman E, Kanjanapan Y, Champiat S, Kato S, Servois V, Kurzrock R, Goel S, Bedard P, Le Tourneau C: Novel patterns of response under immunotherapy. Ann Oncol 2019, 30(3):385-396.
6. Fujimoto D, Yoshioka H, Kataoka Y, Morimoto T, Hata T, Kim YH, Tomii K, Ishida T, Hirabayashi M, Hara S et al: Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy. J Thorac Oncol 2019, 14(3):468-474.
7. Katz SI, Hammer M, Bagley SJ, Aggarwal C, Bauml JM, Thompson JC, Nachiappan AC, Simone CB, 2nd, Langer CJ: Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. J Thorac Oncol 2018, 13(7):978-986.

8. Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, Chaput N, Eggermont A, Marabelle A, Soria JC et al: Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clin Cancer Res 2017, 23(8):1920-1928.

9. Kim CG, Kim KH, Pyo KH, Xin CF, Hong MH, Ahn BC, Kim Y, Choi SJ, Yoon HI, Lee JG et al: Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Ann Oncol 2019, 30:1104-1131.

10. Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G et al: Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria. Clinical Cancer Research 2009, 15(23):7412-7420.

11. Tabatabai R, Natale R: Immunotherapy and Mixed Radiographic Response in Non-Small Cell Lung Cancer. J Cancer Clin 2018, 1(1):1005.

12. Tazdait M, Mezquita L, Lahmar J, Ferrara R, Bidault F, Ammari S, Balleyguier C, Planchard D, Gazzah A, Soria JC et al: Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer 2018, 88:38-47.

13. Nishino M, Dahlberg SE, Adeni AE, Lydon CA, Hatabu H, Janne PA, Hodi FS, Awad MM: Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. Clin Cancer Res 2017, 23(19):5737-5744.

14. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P, Mitchell A, Bolejack V et al: The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016, 11(1):39-51.

15. Nagai Y, Miyazawa H, Huqun, Tanaka T, Udagawa K, Kato M, Fukuyama S, Yokote A, Kobayashi K, Kanazawa M et al: Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005, 65(16):7276-7282.

16. Vanderlaan PA, Yamaguchi N, Folch E, Boucher DH, Kent MS, Gangadharan SP, Majid A, Goldstein MA, Huberman MS, Kocher ON et al: Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer. Lung Cancer 2014, 84(1):39-44.

17. Roach C, Zhang N, Corigliano E, Jansson M, Toland G, Ponto G, Dolled-Filhart M, Emancipator K, Stanforth D, Kulangara K: Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer. 2016, 24(6):392-397.

18. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2):228-247.
19. Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A et al: iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. The Lancet Oncology 2017, 18(3):e143-e152.

20. Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T et al: Programmed Death Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer. J Thorac Oncol 2020:S1556-0864(1520)30373-30377.

21. Lee Y, Kim HY, Lee SH, Lim KY, Lee GK, Yun T, Han JY, Kim HT, Lee JS: Clinical significance of heterogeneity in response to retreatment with epidermal growth factor receptor tyrosine kinase inhibitors in patients with lung cancer acquiring secondary resistance to the drug. Clin Lung Cancer 2014, 15(2):145-151.

22. Kruit WH, van Ojik HH, Brichard VG, Escudier B, Dorval T, Dreno B, Patel P, van Baren N, Avril MF, Piperno S et al: Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer 2005, 117(4):596-604.

23. Jespersen H, Bjursten S, Ny L, Levin M: Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases. The Lancet Oncology 2018, 19(6):e327.

24. Gkiozos I, Kopitopoulou A, Kalkanis A, Vamvakaris IN, Judson MA, Syrigos KN: Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors. J Thorac Oncol 2018, 13(8):1076-1082.

25. Osorio JC, Arbour KC, Le DT, Durham JN, Plodkowski AJ, Halpenny DF, Ginsberg MS, Sawan P, Crompton JG, Yu HA et al: Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade. Journal of Clinical Oncology 2019, 37(36):3546-3555.

26. Remon J, Majem M: EGFR mutation heterogeneity and mixed response to EGFR tyrosine kinase inhibitors of non small cell lung cancer: a clue to overcoming resistance. Transl Lung Cancer Res 2013, 2(6):445-448.

27. Shinno Y, Goto Y, Sato J, Morita R, Matsumoto Y, Murakami S, Kanda S, Horinouchi H, Fujiwara Y, Yamamoto N et al: Mixed response to osimertinib and the beneficial effects of additional local therapy. Thorac Cancer 2019, 10(4):738-743.

28. Dong ZY, Zhai HR, Hou QY, Su J, Liu SY, Yan HH, Li YS, Chen ZY, Zhong WZ, Wu YL: Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer. Oncologist 2017, 22(1):61-69.

29. Chen ZY, Zhong WZ, Zhang XC, Su J, Yang XN, Chen ZH, Yang JJ, Zhou Q, Yan HH, An SJ et al: EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. Oncologist 2012, 17(7):978-985.

Tables

Table 1. Patient characteristics
|                      | Total (%) (N=107) | Dissociated response (N=5) | Concordant response (N=102) | P-value |
|----------------------|-------------------|---------------------------|----------------------------|---------|
| **Age (years)**      |                   |                           |                            |         |
| Mean (SD)            | 68.2 (9.6)        | 69.2 (10.3)               | 68.2 (9.6)                 | 0.81    |
| **Sex**              |                   |                           |                            |         |
| Male                 | 77 (72)           | 3 (60)                    | 74 (73)                    | 0.62    |
| Female               | 30 (28)           | 2 (40)                    | 28 (27)                    |         |
| **Smoking status**   |                   |                           |                            |         |
| Never                | 27 (25)           | 2 (40)                    | 25 (25)                    | 0.60    |
| Current or former    | 80 (75)           | 3 (60)                    | 77 (75)                    |         |
| **Histology**        |                   |                           |                            |         |
| Adenocarcinoma       | 79 (74)           | 4 (80)                    | 75 (74)                    | 1.00*   |
| Squamous cell carcinoma | 22 (21)       | 0 (0)                     | 22 (22)                    |         |
| Others               | 6 (6)             | 1 (20)                    | 5 (5)                      |         |
| **ECOG PS**          |                   |                           |                            |         |
| 0 or 1               | 99 (93)           | 5 (100)                   | 94 (92)                    | 1.00    |
| 2                    | 8 (7)             | 0 (0)                     | 8 (8)                      |         |
| **Stage**            |                   |                           |                            |         |
| IIIB                 | 7 (7)             | 0 (0)                     | 7 (7)                      | 1.00    |
| IV                   | 100 (93)          | 5 (100)                   | 95 (93)                    |         |
| **Mutation status**  |                   |                           |                            |         |
| EGFR or ALK positive | 19 (18)           | 1 (20)                    | 18 (18)                    | 1.00    |
| Wild-type or uninvestigated | 88 (82)     | 4 (80)                    | 84 (82)                    |         |
| **Prior therapy**    |                   |                           |                            |         |
| 1 prior therapy      | 51 (48)           | 2 (40)                    | 49 (48)                    | 1.00    |
| ≥2 prior therapies   | 56 (52)           | 3 (60)                    | 53 (52)                    |         |
| **Tumor response by**|                   |                           |                            |         |
| RECIST  | 0 (0) | 0 (0) | 0 (0) |
|--------|-------|-------|-------|
| CR     | 24 (22)| 0 (0) | 24 (24)|
| PR     | 20 (19)| 2 (40)| 18 (18)|
| SD     | 63 (59)| 3 (60)| 60 (59)|

SD: standard deviation; ECOG PS: Eastern Cooperative Oncology Group Performance Status; EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma kinase; RECIST: Response Evaluation Criteria in Solid Tumors; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease

* Comparison between adenocarcinoma and non-adenocarcinoma